 |
|
Metabolic and Cardiovascular Adverse Events Associated With Antipsychotic Treatment in Children and Adolescents
Roger S. McIntyre, MD, FRCPC;
Jeanette M. Jerrell, PhD
Arch Pediatr Adolesc Med. 2008;162(10):929-935.
Objective To identify factors associated with incident cardiovascular events and metabolic disturbance in children and adolescents treated with antipsychotics.
Design A retrospective cohort design evaluating Medicaid medical and pharmacy claims.
Setting South Carolina's Medicaid program covering outpatient and inpatient medical services and medication prescriptions from January 1, 1996, through December 31, 2005.
Participants A treatment cohort of 4140 children and adolescents prescribed 1 of 5 atypical or 2 conventional antipsychotics, and a random sample of 4500 children not treated with psychotropic medications.
Main Exposure Antipsychotics.
Main Outcome Measures Incidence/prevalence rates for obesity, type 2 diabetes mellitus, dyslipidemia, cardiovascular events, cerebrovascular events, hypertension, and orthostatic hypotension.
Results Compared with the control sample, the treated cohort had a higher prevalence of obesity (odds ratio [OR], 2.13), type 2 diabetes mellitus (OR, 3.23), cardiovascular conditions (OR, 2.70), and orthostatic hypotension (OR, 1.64). In the treated cohort, patients exposed to multiple antipsychotics were at significantly higher risk for incident obesity/weight gain (OR, 2.28), type 2 diabetes mellitus (OR, 2.36), and dyslipidemia (OR, 5.26). Incident cardiovascular events were more likely with the use of conventional (OR, 4.34) or multiple (OR, 1.57) antipsychotics and mood stabilizers (OR, 1.31). Incident orthostatic hypotension was more prevalent in those coprescribed selective serotonin reuptake inhibitors (OR, 1.77) and mood stabilizers (OR, 1.35).
Conclusion Antipsychotics are associated with several metabolic and cardiovascular-related adverse events in pediatric populations, especially when multiple antipsychotics or classes of psychotropic medications are coprescribed, controlling for individual risk factors.
Author Affiliations: Department of Psychiatry and Pharmacology, University of Toronto (Dr McIntyre), and Mood Disorders Psychopharmacology Unit, University Health Network (Dr McIntyre), Toronto, Ontario, Canada; and Department of Neuropsychiatry, University of South Carolina School of Medicine, Columbia (Dr Jerrell).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Antipsychotic Agents and Cardiometabolic Morbidity in Youth
Stefan P. Kruszewski and Richard P. Paczynski
Arch Pediatr Adolesc Med. 2009;163(4):394-395.
EXTRACT
| FULL TEXT
Antipsychotic Agents and Cardiometabolic Morbidity in Youth—Reply
Roger S. McIntyre and Jeanette M. Jerrell
Arch Pediatr Adolesc Med. 2009;163(4):395.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Review on the current use of antipsychotic drugs in children and adolescents
Almandil and Wong
EDUCATION AND PRACTICE 2011;96:192-196.
ABSTRACT
| FULL TEXT
Multiple Psychiatric Diagnoses Common in Privately Insured Children on Atypical Antipsychotics
Halloran et al.
CLIN PEDIATR 2010;49:485-490.
ABSTRACT
Metabolic Screening in Children Receiving Antipsychotic Drug Treatment
Morrato et al.
Arch Pediatr Adolesc Med 2010;164:344-351.
ABSTRACT
| FULL TEXT
Efficacy of Metformin and Topiramate in Prevention and Treatment of Second-Generation Antipsychotic-Induced Weight Gain
Ellinger et al.
The Annals of Pharmacotherapy 2010;44:668-679.
ABSTRACT
| FULL TEXT
Antipsychotic Agents and Cardiometabolic Morbidity in Youth
Kruszewski and Paczynski
Arch Pediatr Adolesc Med 2009;163:394-395.
FULL TEXT
Risk Factors for Cardiac and Metabolic Effects in Children Treated with Antipsychotics
JWatch Pediatrics 2008;2008:2-2.
FULL TEXT
|
